Research archive for JNJ

The Johnson & Johnson share price has been a disappointment over the last 18 months, basically flat while the market has soared. I was encouraged to see them announcing a deal last week to buy Shockwave Medical for $13 billion.

Yesterday, Johnson & Johnson posted results before the US market opened. The company reported better revenue and profit than analysts were expecting, thanks to stronger growth from both the pharmaceutical and medical devices divisions. There isn't a consumer division anymore due to the spin-off of Kenvue in the middle of last year.

Clients have been a little anxious about Johnson & Johnson because it hasn't done much over the last five years. It's been grinding slowly higher, unlike the tech stocks that we own, which have been flying. J&J does have a 3% dividend yield, which is nice. Apart from that, there's not been much to "write home about", as they say.

Johnson & Johnson (J&J) reported solid third quarter numbers yesterday. They earned $2.66 per share, versus the $2.52 that was expected. Sales for the quarter were $21.4 billion, up 6.8% year-on-year.

Johnson & Johnson reported strong second-quarter numbers last week, with increased revenue and profit thanks to a surge in heart procedures and higher demand for cold and flu medicines. The share price popped 6% on the day.

Yesterday, Johnson & Johnson kicked off earnings season for Vestact stocks on a decent note. Revenues came in at $24.7 billion, well above the consensus of $23.6 billion. Earnings per share also had a nice beat, posting $2.68 versus $2.49 expected.

Johnson & Johnson is probably our most boring recommended stock. The company itself has many exciting products, but the share price just plods along, paying out a decent dividend. Due to this stability, J&J was one of our only holdings last year to post positive returns. The reason for their predictable earnings is that they have three major divisions that dovetail nicely with each other. Each quarter, at least one of the parts does well.

Vestact-recommended pharma giant Johnson & Johnson (J&J) reported better-than-expected third-quarter numbers on Tuesday thanks to strong demand from its prescription drug unit. Revenues for the quarter were $23.79 billion, up 1.9% year-on-year and topping estimates. On the other hand, the management team remains concerned about the strong US Dollar and inflation.

Yesterday, before the US market opened, Johnson & Johnson reported their quarterly results. The company is a bit boring but consistent, trotting along with steady and stable growth. Thanks to this predictability, the J&J share price has held all of its value this year, even with the broader market being down about 20%.

Johnson & Johnson reported quarterly earnings yesterday and promptly traded up to a new all-time high, above $185 per share. Almost all Vestact clients own this one, so this is very good news.

Right, so the market took a beating yesterday as reported above. The fall in the Nasdaq of over 2.2% smacked a number of our portfolio holdings. However, Johnson & Johnson rose by 2.6% to reach a new all-time high of $183 a share. So far this year J&J is up 6.5%, whereas the S&P is down 6% and the Nasdaq is down 11.2%. J&J has outperformed the Nasdaq by 17.7% in 3 months. Sometimes it pays to be boring!

Yesterday Johnson & Johnson reported results which beat on earnings but missed on revenue. Sales grew by 10.4% to $24.8 billion, boosted by $1.8 billion in Covid vaccine sales.

On Friday afternoon Johnson & Johnson announced that it would spin off its consumer division, leaving behind the pharmaceutical and medical devices divisions. The consumer business includes brands like Neutrogena, Listerine, Johnson's Baby and Band-Aid. They are doing something similar to General Electric, where shareholder pressure has resulted in the company splitting off very different divisions. The share price jumped 4% on the news but only ended up 1.2% at the market close on Friday evening.

Johnson & Johnson was out with quarterly results before the opening bell yesterday. The numbers were satisfactory, and company guidance for full-year profits was hiked, by 15 cents, to a range of $9.77 to $9.82 a share.

Yesterday, Johnson & Johnson released bumper second-quarter numbers, beating expectations. This was mostly thanks to a great recovery from their pharmaceutical and medical devices businesses, driven higher because individuals can do elective surgeries again without throttling the healthcare system.